SCYNEXIS Presents Data Analyses Showing Ibrexafungerp’s Potential to Fight Invasive…
New interim analysis of the Phase 3 CARES study showed complete or partial response in 78% of the 18 patients treated with ibrexafungerp for infections caused by Candida auris, a…